Related Experiment Video
Updated: Apr 17, 2026
11:31
High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model
Published on: August 16, 2019
8.6K
Combination immunotherapies for type 1 diabetes mellitus
Paolo Pozzilli1, Ernesto Maddaloni1, Raffaella Buzzetti2
1Department of Endocrinology and Diabetes, University Campus Bio-Medico, Via Álvaro del Portillo 21, Rome 00128, Italy.
Nature Reviews. Endocrinology
|February 18, 2015
Summary
Combination immunotherapies aim to restore beta-cell function in type 1 diabetes (T1DM). Novel strategies combine immunomodulators with beta-cell regeneration drugs for a potential cure.
Area of Science:
- Immunology
- Endocrinology
- Regenerative Medicine
Background:
- Type 1 diabetes mellitus (T1DM) research focuses on restoring pancreatic beta-cell function.
- Current immunotherapies for T1DM have yielded disappointing clinical trial results compared to preclinical data.
- T1DM heterogeneity may contribute to treatment failures in previous clinical trials.
Purpose of the Study:
- To review combination immunotherapies for T1DM, focusing on clinical relevance.
- To explore novel combination strategies targeting T1DM's immune and regenerative aspects.
- To discuss the potential of registered drugs like proton pump inhibitors and incretin-based agents in beta-cell regeneration.
Main Methods:
- Review of existing clinical trial data on T1DM immunotherapies.
- Analysis of preclinical studies informing combination therapy development.
- Examination of mechanisms underlying beta-cell destruction and regeneration.
Main Results:
- Clinical outcomes of T1DM immunotherapies have not met expectations.
- Emerging combination therapies integrate immunomodulation with beta-cell regeneration.
- Certain registered drugs show promise for inducing beta-cell regeneration.
Conclusions:
- Combination therapies represent a promising avenue for T1DM treatment.
- Addressing T1DM heterogeneity is crucial for future trial success.
- Integrating immunomodulation with beta-cell regeneration offers a path towards a T1DM cure.
Related Concept Videos
01:22Diabetes Mellitus: Overview and Type I Subtype
6.4K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
6.4K
01:27Tumor Immunotherapy
2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
01:15Diabetes: Management and Pharmacotherapy
1.5K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.5K
01:22Diabetes Mellitus: Type 2 and Gestational
5.9K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.9K
01:16Insulin: Dosing Regimen and Adverse Effects
1.3K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.3K
01:25Immunodeficiency Diseases
3.6K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
There are three main causes of immunodeficiency...
3.6K